Cannabidiol for the treatment of psychosis in Parkinson's disease (Q34830827)

4 August 2017

Cannabidiol for the treatment of psychosis in Parkinson's disease (English)

1 reference

4 August 2017

0 references

0 references

1 reference

1 reference

A W Zuardi

1

1 reference

4 August 2017

J A S Crippa

2

1 reference

4 August 2017

J E C Hallak

3

1 reference

4 August 2017

J P Pinto

4

1 reference

4 August 2017

M H N Chagas

5

1 reference

4 August 2017

G G R Rodrigues

6

1 reference

4 August 2017

S M Dursun

7

1 reference

4 August 2017

V Tumas

8

1 reference

4 August 2017

language of work or name

English

0 references

publication date

18 September 2008

1 reference

Journal of Psychopharmacology

4 August 2017

1 reference

4 August 2017

23

1 reference

4 August 2017

979-983

1 reference

4 August 2017

8

1 reference

Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease.

4 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

A structured interview guide increases Brief Psychiatric Rating Scale reliability in raters with low clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Factor structure of Bech's version of the Brief Psychiatric Rating Scale in Brazilian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

The FAB: a Frontal Assessment Battery at bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Psychotic symptoms in Parkinson's disease patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

The orphan receptor GPR55 is a novel cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

Cannabidiol monotherapy for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108096519

21 January 2018

Identifiers

DOI

10.1177/0269881108096519

1 reference

4 August 2017

1 reference